Interview: Diane Gosselin, President and CEO, CQDM, Canada
The president & CEO of CQDM discusses her vision of how CQDM’s activities can have a direct impact on the development of safer and more efficient drugs, and how to…
CQDM is a not-for-profit organization whose mission is to identify, fund and support joint research projects between the academic and private biopharmaceutical sectors. Projects funded by CQDM target the development of innovative tools and technologies that accelerate the drug discovery process.
Objectives
CQDM is dedicated first and last to the stimulation of research in the field of therapeutic medicine and in particular to the development of innovative tools facilitating the discovery of safer and more effective compounds. By promoting synergy between academic and industrial research and by creating an international exchange network, CQDM intends to expand Quebec’s leadership in biopharmaceutical research and open new research avenues that will have a strong impact on the industry. CQDM activities also benefit small biotechnology companies. Its unique team approach favours access to internationally renowned experts. By leading research efforts towards market expectations, CQDM fully plays its role in disseminating knowledge and creating economic value.
Québec Consortium for Drug Discovery (CQDM)
7140, Albert-Einstein, suite 100
Montreal (Québec) Canada
H4S 2C1
Tel.: 514 766-6661
Fax: 514 766-9613
email: cqdm@cqdm.org
http://www.cqdm.org/en/index.php
The president & CEO of CQDM discusses her vision of how CQDM’s activities can have a direct impact on the development of safer and more efficient drugs, and how to…
Tony Cruz of Transition Therapeutics discusses the challenges of biotech companies in Canada and his company’s unique business model that has adapted to the changing needs of big pharma through…
Tom Reeves of Interface Biologics (IBI) offers his input about the company’s roadmap towards commercialization, as well as IBI’s differentiation and the advantages of collaborating with international partners. You joined…
Sue Paish, Lifelabs’ Chief Executive Officer discusses the company’s recent purchase of BC Biomedical, why the market in BC and Ontario are so attractive, and the motivation behind LifeLabs’ collaboration…
Michael Cloutier, President of InterMune, elaborates on the challenges of navigating the Canadian healthcare system as a small pharmaceutical company, and highlights some methods by which Canada can provide a…
Investissement Québec is a public corporation whose mission is to contribute to Québec’s economic development. Investissement Québec’s project manager, Stéphanie Murphy, discusses the role and contribution of pharmaceutical companies to…
MEDEC is the national association created by and for the Canadian medical technology industry. Brian Lewis, MEDEC’s CEO explains the challanges in advocating for a responsive, safe and sustainable healthcare system…
Charles River is the fifth largest CRO globally and the Canadian affiliate is the largest preclinical organization worldwide. Glenn Washer talks to us about the environment for contract research in…
Rémi Quirion, Chief Scientist of Québec, discusses how Canada needs to promote itself more aggressively, and highlights ways in which Canada can use industry-academia partnerships to its advantage, as well…
Wayne Samuels, partner at PwC Canada, discusses the most pressing issues in the country’s healthcare system and pharmaceutical industry, and outlines the changing dynamics in Canada’s pharma business model. What…
Michael Seckler of Ferring Canada offers his input about the affiliate’s recent restructuring, as well as the challenges of Canada’s reimbursement and pricing schemes and the advantages of the company’s…
Kevin Leshuk, Vice-President and General Manager of Celgene in Canada, offers his critique of the Canadian reimbursement and approval process as well as the advantages his affiliate enjoys in specialty…
Hervé Lilliu, General Manager of UCB Canada, describes Canada’s need to support the global pharma-ceutical industry rather than vice versa, and highlights examples of ways in which Canada’s slumbering R&D…
See our Cookie Privacy Policy Here